Trials / Completed
CompletedNCT05579899
Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis
A Randomized, Vehicle-controlled, Safety and Efficacy Study of EVO101 in Adult Subjects With Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 119 (actual)
- Sponsor
- Evommune, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2a safety and efficacy study of EVO101 for the treatment of adults with atopic dermatitis
Detailed description
This is a Phase 2a safety and efficacy study of EVO101 Topical Cream, 0.1%, applied twice daily for 8 weeks in adults with mild-to moderate atopic dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EVO101 | Topical Cream |
Timeline
- Start date
- 2022-09-27
- Primary completion
- 2023-07-27
- Completion
- 2023-07-27
- First posted
- 2022-10-14
- Last updated
- 2025-03-05
- Results posted
- 2025-03-05
Locations
21 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05579899. Inclusion in this directory is not an endorsement.